Connect Biopharma reports Q1 EPS (19c) vs (16c) last year

“The first quarter of 2025 was very productive, including a positive Type C meeting with the U.S. Food and Drug Administration, publication of our previously completed global Phase 2 trial results in the American Journal of Respiratory and Critical Care Medicine, and acceptance of four posters to be presented at the American Thoracic Society 2025 International Conference,” said Barry Quart, Pharm.D., CEO and Director of Connect Biopharma (CNTB). “We are focused on execution as we advance our clinical development plan for rademikibart, and we were pleased to initiate the Seabreeze STAT studies evaluating rademikibart as an adjunct treatment for acute exacerbations in both asthma and COPD. Based on our recently published data in the AJRCCM and our upcoming presentations at ATS 2025 International Conference, we are excited by rademikibart’s potential to be the first biologic to rapidly deliver significant improvements in lung function for patients being treated for an acute exacerbation. We are working diligently to enroll patients and we remain well capitalized to deliver topline data in both studies in the first half of 2026.”